Imagine having a migraine more days than not, and then finding that the very pills you take for relief are actually making the problem worse. This frustrating cycle, called medication-overuse headache, traps many people with chronic migraine. A new study looked at whether a two-part strategy could help: a preventive drug called eptinezumab, given by IV, plus a short, structured conversation with a doctor about medication use.
The research involved nearly 600 adults from clinics around the world who were living with both conditions. Over the first month, those who received the drug plus education saw their migraine days drop by nearly 7 days on average, compared to a drop of about 4 days for those who got a placebo IV plus the same education. That's a meaningful difference of about 3 fewer migraine days. The drug was generally well-tolerated, with side effects similar to the placebo group.
It's important to understand what this study does and doesn't tell us. The benefit came from the combination of the drug and the education—we can't separate out how much each part contributed. The results also only cover 12 weeks, so we don't know if the improvement lasts. For people caught in this specific, difficult pain cycle, the findings point to a potential new path forward, but one that needs more time and study to fully map out.